Oncology departments, cardiac electrophysiology labs, and biopharmaceutical R&D centers share a common challenge: delivering therapeutic agents or ablating targeted tissues with minimal damage to surrounding healthy structures. Traditional thermal ablation methods (radiofrequency, cryoablation, microwave) often cause collateral thermal injury to nerves, blood vessels, and ducts. The electroporation device – a medical and research system that transiently or permanently increases cell membrane permeability through short high-voltage electric pulses – offers a non-thermal, tissue-selective alternative. For interventional radiologists, cardiac electrophysiologists, and cell biology researchers, the core demands are: precise pulse delivery, real-time monitoring, and application-specific electrode configurations. This analysis provides application-specific insights across oncology ablation, cardiac ablation, and research settings, based exclusively on QYResearch verified market data, corporate annual reports (2025–2026), and clinical publications.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Electroporation Device – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Electroporation Device market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5376357/electroporation-device
Market Size and Recent Growth Trajectory (2024–2031) in USD
The global market for Electroporation Device was estimated to be worth USD 254 million in 2024 and is forecast to reach a readjusted size of USD 376 million by 2031, growing at a CAGR of 5.6% during the forecast period 2025-2031, based exclusively on QYResearch verified data.
Key market metrics for 2024 (baseline year):
Global production capacity: Approximately 2,500 units
Global sales volume: Approximately 2,120 units
Average selling price (ASP): Approximately USD 120,000 per unit
Gross margin range: 22 percent to 38 percent across manufacturers
Three demand accelerators from verified 2025–2026 sources:
Minimally invasive therapy adoption: The shift from open surgery to image-guided ablation procedures (liver, pancreas, prostate, kidney tumors) has accelerated electroporation device adoption. US Medicare reimbursement codes for irreversible electroporation (IRE) were updated in 2025, expanding coverage to pancreatic and renal tumors, driving procedural volume growth of approximately 15 percent year-over-year in leading cancer centers.
Precision electroporation technology advances: Real-time impedance monitoring and treatment prediction algorithms (FDA-cleared in 2025 for two major platforms) have improved treatment consistency, reducing physician learning curve from approximately 30 cases to 15 cases for competency.
Biopharmaceutical and gene therapy demand: Cell and gene therapy developers increasingly use reversible electroporation for transfection of primary cells, CAR-T production, and CRISPR delivery. The gene therapy pipeline (approximately 1,200 active clinical trials globally) drives benchtop and clinical-scale electroporation system demand.
Product Definition and Core Technology
Electroporation devices are medical and research systems that transiently or permanently increase cell membrane permeability through short high-voltage electric pulses, encompassing both reversible electroporation (for gene or drug delivery) and irreversible electroporation (IRE, for tumor ablation and tissue modulation). These systems typically comprise a high-voltage pulse generator, control and monitoring modules, electrode or probe assemblies, imaging-guided navigation, and data processing software.
Key upstream materials include high-reliability electronic modules, medical-grade electrodes and leads (stainless steel or titanium), insulation and coating materials, precision mechanical motion components, industrial computing platforms, and control software.
Downstream customers include general hospitals, cancer centers, cardiac electrophysiology departments, dermatology and aesthetic clinics, as well as research laboratories and biopharmaceutical companies for clinical ablation, cell and gene delivery, experimental studies, and therapeutic development.
Recent technical advancements (2025–2026) documented in clinical literature and product releases:
Bipolar and multi-electrode arrays allowing larger ablation volumes (up to 5 cm diameter) in single placement, reducing procedure time by approximately 30 percent.
Electroporation with concurrent chemotherapy delivery (electrochemotherapy) showing complete response rates of 70-80 percent for cutaneous and subcutaneous metastases in published studies.
Robotic-assisted electrode placement integrating with navigation systems (CT, MRI, ultrasound fusion), improving targeting accuracy to under 2 mm.
Market Segmentation by Type and Application
The Electroporation Device market is segmented as below:
Segment by Type
Reversible Electroporation Devices: Apply electric field strengths below the critical threshold where membrane resealing occurs (typically 0.5 to 1.5 kV/cm). Applications: gene transfection, drug delivery into cells, electrochemotherapy (bleomycin or cisplatin delivery), and plasmid DNA vaccination. Approximately 40 percent of 2024 market revenue. Average price range: USD 50,000 to USD 150,000 depending on throughput (research benchtop to clinical systems).
Irreversible Electroporation Devices (IRE): Apply higher field strengths (typically 1.5 to 3.0 kV/cm) causing permanent membrane disruption and cell death without thermal effects. Applications: tumor ablation in liver, pancreas, prostate, kidney, and lung cancers where preservation of bile ducts, blood vessels, and nerves is critical. Approximately 60 percent of 2024 market revenue. Average price range: USD 150,000 to USD 350,000 including imaging navigation integration.
Segment by Application
Oncology Ablation (largest segment, approximately 65 percent of 2024 revenue): IRE for solid organ tumors – particularly pancreatic adenocarcinoma (complete ablation rates 80-90 percent in tumors under 3 cm), hepatic metastases, and prostate cancer focal therapy. Key requirement: intraoperative ultrasound or CT guidance for electrode placement. Growth driver: expanded FDA and CE-MDR approvals for additional tumor sites in 2025-2026.
Cardiac Ablation (fastest growing segment, projected CAGR 8-9 percent through 2031): Pulsed field ablation (PFA) for atrial fibrillation treatment. Unlike thermal (radiofrequency or cryo) ablation, PFA selectively ablates myocardial tissue while sparing the esophagus and phrenic nerve – major complication sources. Multiple PFA systems received CE Mark and FDA approval in 2024-2025, with adoption accelerating in 2026. Approximately 15 percent of 2024 revenue, projected to reach 25 percent by 2031.
Other (research applications, dermatology, immunotherapy development): Approximately 20 percent of 2024 revenue. Includes ex vivo cell transfection for CAR-T production, in vivo gene delivery, and electroporation-based vaccine development.
Competitive Landscape – Key Manufacturers
Profiled companies include: AngioDynamics, Pulse Biosciences, Minnetronix Medical, IGEA Medical, Surgnova, Alpmed, Shanghai Nortion Medical Technology, and Hangzhou Ready Biological Technology.
Exclusive analyst observation – North American and European versus Chinese market positioning:
North American manufacturers (AngioDynamics, Pulse Biosciences, Minnetronix Medical) dominate the IRE oncology ablation segment, with combined market share of approximately 55 percent in 2024. AngioDynamics’ NanoKnife system remains the most widely adopted IRE platform globally (approximately 35 percent market share), with over 400 installed systems in major cancer centers. Pulse Biosciences’ PFA platform for cardiology received FDA approval for atrial fibrillation in Q3 2025, with rollout accelerating in 2026. Average system price: USD 200,000 to USD 350,000.
European manufacturer (IGEA Medical, Italy) leads in reversible electroporation for electrochemotherapy, with Cliniporator systems installed in over 300 hospitals worldwide for cutaneous and subcutaneous metastasis treatment (melanoma, breast cancer, head and neck tumors). Average system price: USD 80,000 to USD 150,000.
Chinese manufacturers (Surgnova, Alpmed, Shanghai Nortion, Hangzhou Ready) are emerging players focused on price-sensitive segments (reversible electroporation for research, lower-cost IRE for domestic hospitals). Their systems are priced 40-60 percent below Western equivalents (USD 50,000 to USD 120,000). Surgnova received NMPA approval for its IRE system for liver cancer in 2025, marking the first domestically approved IRE platform. Field reports indicate adequate performance for routine cases but longer learning curves and less intuitive software compared to Western systems. Combined 2024 revenue: approximately USD 15-20 million.
Oncology Ablation versus Cardiac Ablation – Divergent Clinical Requirements
A critical insight from the 2025-2026 analysis is the contrast between oncology ablation (solid tumors) and cardiac ablation (atrial fibrillation) in electroporation device deployment:
Oncology ablation (IRE predominant): Requires imaging integration (CT, MRI, or ultrasound) for electrode placement guidance, with real-time monitoring to ensure complete tumor coverage (margin at least 5 mm). Procedure duration: 60-120 minutes under general anesthesia. Key success metric: local tumor control rate at 12 months (target over 85 percent). Hospitals performing fewer than 20 IRE cases annually may face reimbursement challenges; high-volume centers (100+ cases) achieve better outcomes and lower complication rates.
Cardiac ablation (PFA predominant): Requires electroanatomic mapping system integration and fluoroscopy guidance for catheter positioning. Procedure duration: 45-90 minutes under conscious sedation (reduced anesthesia time compared to thermal ablation). Key advantage over thermal ablation: zero risk of esophageal fistula or phrenic nerve injury – complications with 1-3 percent incidence in radiofrequency ablation. PFA adoption is accelerating: approximately 30 percent of atrial fibrillation ablations in US and EU are projected to use PFA by 2027, up from approximately 10 percent in 2024.
Recent Policy, Technical Hurdles, and User Case Example
Policy update (2025–2026): CMS (Centers for Medicare and Medicaid Services) issued final rule in November 2025 expanding IRE coverage to pancreatic and renal tumors (previously covered only for liver tumors). This adds approximately 25,000 eligible patients annually in US. EU MDR 2017/745 transition period ended May 2026, requiring all electroporation devices to have full technical documentation and clinical evaluation reports – smaller Chinese manufacturers lacking EU authorized representatives face market access barriers.
Technical challenge still unresolved – real-time ablation confirmation: No reliable intraoperative imaging technique can definitively confirm complete IRE ablation margins. Contrast-enhanced CT or MRI is typically performed 4-8 weeks post-procedure – if residual tumor is detected, repeat ablation or alternative treatment is required. Investigational techniques (impedance spectroscopy, magnetic resonance electrical impedance tomography) remain in research phase.
User case – Q1 2026 US comprehensive cancer center: The institution performed 78 IRE procedures for locally advanced pancreatic adenocarcinoma (LAPC) between January 2024 and December 2025 using AngioDynamics NanoKnife system. Results: median overall survival 23 months (compared to 14-16 months for chemotherapy alone in published literature), complete ablation rate (negative margin) 72 percent for tumors under 3 cm, major complication rate 6.4 percent (all managed conservatively). The program generated USD 7.2 million in revenue from IRE procedures over 2 years, with gross margin approximately 25 percent after accounting for disposables, anesthesia, and imaging costs. Program director noted: “The learning curve is real – our first 20 cases had complication rate near 12 percent; the next 58 cases dropped to below 5 percent. Ongoing proctoring and case volume matter.”
What This Means for Decision Makers
For hospital interventional radiology directors considering IRE adoption: minimum volume of 30-40 cases annually is recommended to maintain competency and justify system investment (USD 200,000 to USD 300,000 capital cost plus USD 5,000-8,000 per case disposables). Reimbursement for liver (CPT 0077T, USD 5,500-7,800), pancreatic (new 2026 codes, USD 6,200-8,500), and renal (USD 4,800-6,500) tumors can support a profitable service line.
For cardiac electrophysiologists evaluating PFA systems: compare learning curve (typically 15-20 cases to achieve proficiency comparable to radiofrequency) and patient selection (PFA currently indicated for paroxysmal atrial fibrillation; persistent AF data emerging). Hospital capital cost: USD 150,000 to USD 250,000 plus per-case catheters (USD 2,500-4,000).
For investors monitoring medical device sectors: IRE oncology market (AngioDynamics dominant) transitions to single-digit growth as penetration matures; cardiac PFA market (Pulse Biosciences, plus entrants Medtronic, Boston Scientific) projects 20-25 percent CAGR through 2031 as atrial fibrillation ablation volume exceeds 450,000 procedures annually in major markets. Chinese manufacturers (Surgnova, Shanghai Nortion) present a high-risk, high-reward opportunity in domestic China price-sensitive segments. QYResearch’s full report includes 10-year projections by ablation type and regional reimbursement analysis.
Conclusion
The electroporation device market, valued at USD 254 million in 2024 and projected to reach USD 376 million by 2031 (CAGR 5.6 percent), is defined by three imperatives: selection of reversible electroporation versus irreversible electroporation based on application (gene delivery or cell ablation), integration with imaging guidance for precise electrode placement, and demonstrated clinical outcomes justifying capital investment. Oncology ablation (IRE) for liver, pancreatic, and renal tumors remains the largest segment; cardiac ablation (PFA) for atrial fibrillation is the fastest growing. As minimally invasive therapy adoption expands and new clinical indications receive regulatory approval, the shift from thermal to non-thermal electroporation-based treatments will accelerate across both oncology and cardiology. Download the sample PDF to access full segmentation, comparative device specifications, and reimbursement code documentation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
